速遞｜13億美元！禮來拿下英偉達投資AI發現的新口服減肥藥

GLP1減重寶典

2025/08/17

整理 | GLP1減重寶典內容團隊禮來公司（LLY.N）與私人持有的Superluminal Medicines達成一項價值13億美元的合作協議，利用人工智能發現並開發用於治療肥胖和其他心臟代謝疾病的小分子藥物。禮來目前在快速增長的肥胖治療市場中佔據主導地位，該市場預計到下一個十年將達到1500億美元。公司正通過研發新一代藥物、收購以及合作來進一步擴大影響力。根據協議，禮來將獲得獨家權利，開發和...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560294019"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560294019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560294019?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-17 11:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2560294019","market":"us","top_or_hot":-1,"title":"速遞｜13億美元！禮來拿下英偉達投資AI發現的新口服減肥藥","media":"GLP1減重寶典","content":"<div>\n<p>整理 | GLP1減重寶典內容團隊禮來公司（LLY.N）與私人持有的Superluminal Medicines達成一項價值13億美元的合作協議，利用人工智能發現並開發用於治療肥胖和其他心臟代謝疾病的小分子藥物。禮來目前在快速增長的肥胖治療市場中佔據主導地位，該市場預計到下一個十年將達到1500億美元。公司正通過研發新一代藥物、收購以及合作來進一步擴大影響力。根據協議，禮來將獲得獨家權利，開發和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817112706a6ea92cd&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速遞｜13億美元！禮來拿下英偉達投資AI發現的新口服減肥藥</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速遞｜13億美元！禮來拿下英偉達投資AI發現的新口服減肥藥\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GLP1減重寶典</strong><span class=\"h-time small\">2025-08-17 11:02</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>整理 | GLP1減重寶典內容團隊禮來公司（LLY.N）與私人持有的Superluminal Medicines達成一項價值13億美元的合作協議，利用人工智能發現並開發用於治療肥胖和其他心臟代謝疾病的小分子藥物。禮來目前在快速增長的肥胖治療市場中佔據主導地位，該市場預計到下一個十年將達到1500億美元。公司正通過研發新一代藥物、收購以及合作來進一步擴大影響力。根據協議，禮來將獲得獨家權利，開發和...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817112706a6ea92cd&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817112706a6ea92cd&s=b\">GLP1減重寶典</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKDWB100.SGD","symbol_name":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817112706a6ea92cd&s=b","article_id":"2560294019","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817112706a6ea92cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2560294019","pubTimestamp":1755399763,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"整理 | GLP1減重寶典內容團隊禮來公司與私人持有的Superluminal Medicines達成一項價值13億美元的合作協議，利用人工智能發現並開發用於治療肥胖和其他心臟代謝疾病的小分子藥物。禮來目前在快速增長的肥胖治療市場中佔據主導地位，該市場預計到下一個十年將達到1500億美元。根據協議，禮來將獲得獨家權利，開發和商業化利用Superluminal專有AI平台發現的候選藥物。禮來正在研發備受關注的口服GLP-1藥物orforglipron，但其表現未達到投資者預期。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","NVDS":"1.5倍做空NVDA ETF-Tradr","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NVDU":"2倍做多NVDA ETF-Direxion","NVD2.UK":"2X NVIDIA ETP","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4567":"ESG概念","LLY":"礼来","3NVD.UK":"LS 3X NVIDIA","NVD3.UK":"LS 3X NVIDIA","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","NVDX":"2倍做多NVDA ETF-T-Rex","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU0476273544.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"BU\" (USD) ACC","NVDS.UK":"LS -1X NVIDIA","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","NVD":"2倍做空NVDA ETF-GraniteShares","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","LU0788109477.HKD":"BGF GLOBAL ALLOCATION \"A2\" (HKDHGD) ACC","NVDY":"NVDA期权收益策略ETF-YieldMax","2NVD.UK":"2X NVIDIA ETP","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999000418.SGD":"Aberdeen Standard Global Technology SGD","NVDD":"1倍做空NVDA ETF-Direxion","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SNVD.UK":"LS -1X NVIDIA","NVIW.SI":"NVDA 3xLongSG261006","LU2242650005.HKD":"FIDELITY FUNDS GLOBAL MULTI ASSET DYNAMIC \"A\" (HKD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","BK4614":"Manus概念股","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4548":"巴美列捷福持仓","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1992135399.USD":"Allianz Global Intelligent Cities AT Acc USD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0308772762.SGD":"Blackrock Global Allocation A2 SGD-H"},"translate_title":"Express | $1.3 billion! Eli Lilly wins new oral diet pill discovered by Nvidia's investment in AI","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVDS":0.6,"SNVD.UK":0.6,"NVDD":0.6,"NVIW.SI":0.6,"NVD2.UK":0.6,"NVDX":0.6,"LLY":1,"3NVD.UK":0.6,"2NVD.UK":0.6,"NVDU":0.6,"NVDS.UK":0.6,"NVDY":0.6,"NVD":0.6,"NVD3.UK":0.6},"content_text":"整理 | GLP1減重寶典內容團隊禮來公司（LLY.N）與私人持有的Superluminal Medicines達成一項價值13億美元的合作協議，利用人工智能發現並開發用於治療肥胖和其他心臟代謝疾病的小分子藥物。禮來目前在快速增長的肥胖治療市場中佔據主導地位，該市場預計到下一個十年將達到1500億美元。公司正通過研發新一代藥物、收購以及合作來進一步擴大影響力。根據協議，禮來將獲得獨家權利，開發和商業化利用Superluminal專有AI平台發現的候選藥物。該平台的研究重點是G蛋白偶聯受體（GPCR），這類蛋白能影響代謝、細胞生長和免疫反應。包括丹麥競爭對手諾和諾德（NOVOb.CO）在內的多家制藥商正探索GPCR靶點，以開發口服小分子肥胖治療藥物。「GPCR已在肥胖和代謝疾病領域展現出重要價值，但我們仍處於探索的早期階段，」Superluminal首席執行官Cony D'Cruz對路透社表示。今年5月，諾和諾德與美國生物科技公司Septerna達成22億美元合作，開發針對特定GPCR靶點的小分子療法。禮來也在鞏固其在GLP-1藥物領域的領先地位，旗下暢銷藥物Zepbound以及諾和諾德的Wegovy都屬於這一類別。禮來正在研發備受關注的口服GLP-1藥物orforglipron，但其表現未達到投資者預期。去年，禮來還與港股上市公司萊納生物（2105.HK）合作，開發一種實驗性肥胖藥物，旨在幫助患者減重的同時保留肌肉質量。根據合作條款，Superluminal有資格獲得預付款、里程碑付款、股權投資以及基於銷售額的分級版税。總部位於波士頓的Superluminal正在研發一款自有的核心候選藥物，靶向黑皮質素4受體（MC4R），用於治療某些罕見的遺傳性肥胖，預計將在明年第四季度進入人體臨床試驗。該候選藥物不包含在與禮來的合作中。Superluminal的投資方包括RA Capital Management、Insight Partners和英偉達旗下風險投資部門NVentures。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}